Korean J Intern Med.
2011 Jun;26(2):153-159. 10.3904/kjim.2011.26.2.153.
Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
- Affiliations
-
- 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea. yimjj@snu.ac.kr
- 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
- 3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- 4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- KMID: 1776587
- DOI: http://doi.org/10.3904/kjim.2011.26.2.153
Abstract
- BACKGROUND/AIMS
To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB).
METHODS
A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed).
RESULTS
The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65).
CONCLUSIONS
Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.
MeSH Terms
-
Adult
Antitubercular Agents/adverse effects/*therapeutic use
Aza Compounds/adverse effects/*therapeutic use
Case-Control Studies
Chi-Square Distribution
*Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Extensively Drug-Resistant Tuberculosis/*drug therapy/microbiology/mortality
Female
Humans
Logistic Models
Male
Middle Aged
Mycobacterium tuberculosis/*drug effects/pathogenicity
Odds Ratio
Ofloxacin/adverse effects/*therapeutic use
Quinolines/adverse effects/*therapeutic use
Recurrence
Remission Induction
Republic of Korea
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Tuberculosis, Multidrug-Resistant/*drug therapy/microbiology/mortality
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis
- Activity of Moxifloxacin Against Ofloxacin-Resistant Mycobacterium Tuberculosis: A Study of Cross-Resistance Between Ofloxacin and Moxifloxacin
- Diagnosis and Treatment of Multidrug-Resistant Tuberculosis
- Treatment of pulmonary tuberculosis
- Respiratory Review of 2014: Tuberculosis and Nontuberculous Mycobacterial Pulmonary Disease
